COG : Gefitinib for oesophageal cancer progressing after chemotherapy

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

COG: Randomised Phase 3 trial of gefitnib 500mg once daily versus placebo in oesophageal cancer progressing after chemotherapy

Primary Publication: The Lancet Oncology Volume 15, ISSUE 8, July 2014

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial